home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Dendritic Cells Need CD4 T Cells To Activate Killer T Cells

 
  November, 9 2001 1:38
your information resource in human molecular genetics
 
     
Contrary to what was previously thought, the maturation state of dendritic cells is not what determines whether the immune system's killer T cells are activated or not. In the November issue of Nature Immunology, scientists from the Rockefeller University, New York show that mature DCs depend on the presence of CD4 T cells, to activate, rather than shut down, CD8 killer T cells.

This is a critical distinction. The immune system must discriminate between the self proteins and pathogenic infectious agents. A reaction to the former initiates the tissue destruction known as autoimmunity. Fortunately, most autoreactive CD8 T cells are eliminated in the thymus, but some do escape. These potentially self-destructive CD8 T cells can be tolerized (that is, made unresponsive, or tolerant, to its specific antigen) by interactions with dendritic cells. Immature dendritic cells take up proteins, which they then take with them to the lymph nodes, maturing in the process. In the nodes the mature dendritic cells encounter CD8 T cells, which are then either activated or tolerized, depending on whether the protein is foreign or self.

The old paradigm to explain how dendritic cells can both tolerize and activate CD8 T cells depended upon the stage of dendritic cell development, because immature DCs could only deliver one signal (which results in tolerance) to the CD8 T cell, whereas mature DCs can deliver two. Albert and colleagues suggest a new model: the critical checkpoint is not dendritic cell maturation, but instead the presence of a third signal, which is provided by CD4 T cells.

Author contact:
Matthew L. Albert
Laboratory of Neuro-Immunology, Rockefeller University, New York, USA
Tel: +1 212 327 7451
E-mail albertm@rockvax.rockefeller.edu

Additional contact for comment on paper:
Ken Shortman
Immunology Division, Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia
Tel: +61 393 452 531
E-mail shortman@wehi.edu.au

(C) Nature Immunology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.